港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

派格生物醫藥-B

8.830

+0.0100.11%

成交量：4,099.26萬

成交額：3.78億

市值：34.53億

市盈率：-13.88

高：10.480

開：9.260

低：8.430

收：8.820

52周最高：77.000

52周最低：7.460

股本：3.91億

香港流通股本：2.84億

量比：1.75

換手率：14.43%

股息：- -

股息率：- -

每股收益(LYR):-0.636

淨資產收益率：-82.42%

總資產收益率：-31.46%

市淨率：6.65

市盈率(LYR):-13.88

市銷率: -770.17

資料載入中...

總覽公司新聞資訊公告

派格生物醫藥-B(02565)：維培那肽注射液納入2026年第二批參照藥預溝通增補藥品信息公示

異動解讀 | 派格生物醫藥-B盤中大漲5.33%，超跌反彈成主因

異動解讀｜派格生物醫藥-B盤中上漲10.77%，解禁拋壓集中釋放後技術性反彈

異動解讀｜派格生物醫藥-B盤中下跌15.99%，上市滿周年禁售期全面解禁引發拋壓

格隆匯個股放量排行榜 | 5月25日

異動解讀 | 派格生物醫藥-B盤中大漲5.02%，核心藥物商業化合作獲重大進展

異動解讀｜派格生物醫藥-B盤中上漲7.54%，GLP-1藥物商業化預期疊加短期超跌反彈

異動解讀 | 派格生物醫藥-B盤中大跌6.96%，前期暴漲後技術性回調

異動解讀｜派格生物醫藥-B盤中下跌5.14%，前期暴漲後回調縮量

派格生物醫藥－Ｂ(02565)股價下跌5.007%，現價港幣$14.61

阿斯达克财经

異動解讀 | 派達康商業化加速，派格生物醫藥-B盤中大漲6.86%

異動解讀｜派格生物醫藥-B盤中上漲8.37%，派達康商業化落地持續催化

派格生物醫藥-B(02565)提名廖亦琳為獨立非執行董事候選人

異動解讀 | 派達康商業化合作持續催化，派格生物醫藥-B盤中大漲28.96%

港股異動 | 派格生物醫藥-B(02565)尾盤飆升150% 此前與騰瑞製藥達成派達康中國大陸獨家商業化合作

派格生物醫藥－Ｂ(02565)股價顯著上升11.171%，現價港幣$12.44

阿斯达克财经

「2026智通財經夏季路演大會」活動報名中！

智通财经网

派格生物醫藥－Ｂ(02565)股價下跌5.141%，現價港幣$22.88

阿斯达克财经

派格生物醫藥－Ｂ(02565)股價上升8.679%，現價港幣$27.8

阿斯达克财经

派格生物醫藥-B2026年4月股份維持穩定無新增發行或回購

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/02565/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02565","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02565\",,,,,undefined,":{"symbol":"02565","market":"HK","secType":"STK","nameCN":"派格生物醫藥-B","latestPrice":8.83,"timestamp":1779955711008,"preClose":8.82,"halted":0,"volume":40992550,"delay":0,"changeRate":0.001133786848072538,"floatShares":284000000,"shares":391000000,"eps":-0.6362474734021717,"marketStatus":"未開盤","change":0.01,"latestTime":"05-28 16:08:31","open":9.26,"high":10.48,"low":8.43,"amount":377971383,"amplitude":0.232426,"askPrice":8.83,"askSize":65000,"bidPrice":8.82,"bidSize":40050,"shortable":3,"etf":0,"ttmEps":-0.6362474734021717,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1780018200000},"marketStatusCode":0,"adr":0,"listingDate":1748275200000,"exchange":"SEHK","adjPreClose":8.82,"openAndCloseTimeList":[[1779931800000,1779940800000],[1779944400000,1779955200000]],"volumeRatio":1.752982,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02565\",,,,,undefined,":{"symbol":"02565","floatShares":284000000,"roa":"-31.46%","roe":"-82.42%","lyrEps":-0.636274,"volumeRatio":1.752982,"shares":391000000,"dividePrice":0,"high":10.48,"amplitude":0.232426,"preClose":8.82,"low":8.43,"week52Low":7.46,"pbRate":"6.65","psRate":"-770.17","week52High":77,"institutionHeld":0,"latestPrice":8.83,"committee":-0.237506,"eps":-0.6362740028674172,"divideRate":0,"volume":40992550,"delay":0,"ttmEps":-0.6362740028674172,"open":9.26,"prevYearClose":69,"prevWeekClose":12.94,"prevMonthClose":24.64,"prevQuarterClose":58,"fiveDayClose":15.38,"twentyDayClose":26.38,"sixtyDayClose":64.2},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02565\",params:#limit:5,,,undefined,":[{"market":"HK","date":"2026-03-23","symbol":"02565","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1774195200000,"reportTimeType":"post","actualEps":null},{"date":"2025-08-26","symbol":"02565","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756171800000,"name":null,"time":"","dateTimestamp":1756137600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02565\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02565\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02565\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02565","date":"2026-05-27","current":-13.89729,"percent":0.869198,"low":-87.782868,"twenty":-73.777626,"median":-61.31588,"eighty":-19.117647,"high":-11.114373,"avg":-52.767999,"sd":24.924517,"marketCap":3449427312},"quantilePoints":[{"date":"2025-05-30","current":-12.743079,"twenty":-15.470266,"median":-13.542645,"eighty":-13.135794,"marketCap":3936746426},{"date":"2025-06-06","current":-11.987888,"twenty":-13.726785,"median":-12.740515,"eighty":-12.114178,"marketCap":3712892217},{"date":"2025-06-13","current":-11.23576,"twenty":-13.295707,"median":-12.114337,"eighty":-11.528404,"marketCap":3481318898},{"date":"2025-06-20","current":-11.30775,"twenty":-12.841258,"median":-11.963331,"eighty":-11.337793,"marketCap":3496757119},{"date":"2025-06-27","current":-12.421214,"twenty":-12.738977,"median":-11.541778,"eighty":-11.292079,"marketCap":3851836209},{"date":"2025-07-04","current":-13.963875,"twenty":-12.971799,"median":-11.987888,"eighty":-11.299391,"marketCap":4330421069},{"date":"2025-07-11","current":-13.604213,"twenty":-13.050401,"median":-12.199189,"eighty":-11.305737,"marketCap":4214634409},{"date":"2025-07-18","current":-16.956264,"twenty":-13.748078,"median":-12.438987,"eighty":-11.330282,"marketCap":5248995235},{"date":"2025-07-25","current":-19.006677,"twenty":-15.472199,"median":-12.742066,"eighty":-11.352726,"marketCap":5905119639},{"date":"2025-08-01","current":-19.199848,"twenty":-18.276271,"median":-12.906561,"eighty":-11.424474,"marketCap":5928276971},{"date":"2025-08-08","current":-20.51103,"twenty":-19.019895,"median":-13.05938,"eighty":-11.472546,"marketCap":6348968501},{"date":"2025-08-15","current":-39.959751,"twenty":-19.179784,"median":-13.542645,"eighty":-11.515029,"marketCap":12350577024},{"date":"2025-08-22","current":-41.864246,"twenty":-19.284777,"median":-13.964282,"eighty":-11.779976,"marketCap":12898633879},{"date":"2025-08-29","current":-41.44792,"twenty":-21.432837,"median":-14.946806,"eighty":-11.968242,"marketCap":10033166343},{"date":"2025-09-05","current":-50.678037,"twenty":-39.039264,"median":-17.018603,"eighty":-12.06328,"marketCap":12255314482},{"date":"2025-09-12","current":-58.538001,"twenty":-40.749762,"median":-18.438762,"eighty":-12.114019,"marketCap":14181548421},{"date":"2025-09-19","current":-57.311117,"twenty":-43.720929,"median":-18.952908,"eighty":-12.216159,"marketCap":13874467648},{"date":"2025-09-26","current":-63.587749,"twenty":-49.33228,"median":-19.070122,"eighty":-12.366345,"marketCap":15354038645},{"date":"2025-10-03","current":-60.149194,"twenty":-54.575673,"median":-19.16943,"eighty":-12.428323,"marketCap":14558420278},{"date":"2025-10-10","current":-60.121463,"twenty":-57.957283,"median":-19.199848,"eighty":-12.49878,"marketCap":14530503844},{"date":"2025-10-17","current":-60.168303,"twenty":-59.756564,"median":-19.2984,"eighty":-12.738571,"marketCap":14530503844},{"date":"2025-10-24","current":-61.301982,"twenty":-60.143648,"median":-20.51103,"eighty":-12.741458,"marketCap":14809668183},{"date":"2025-10-31","current":-69.345185,"twenty":-60.159469,"median":-22.018639,"eighty":-12.743079,"marketCap":16777776773},{"date":"2025-11-07","current":-59.401661,"twenty":-60.392128,"median":-34.33922,"eighty":-12.780248,"marketCap":14363005241},{"date":"2025-11-14","current":-72.819022,"twenty":-61.035505,"median":-39.959751,"eighty":-12.906561,"marketCap":17657144441},{"date":"2025-11-21","current":-72.852961,"twenty":-61.301982,"median":-40.866122,"eighty":-12.943343,"marketCap":17657144441},{"date":"2025-11-28","current":-82.344376,"twenty":-62.346137,"median":-42.423494,"eighty":-13.014482,"marketCap":20030041323},{"date":"2025-12-05","current":-72.063717,"twenty":-63.355663,"median":-45.122001,"eighty":-13.104279,"marketCap":17559436923},{"date":"2025-12-12","current":-74.217813,"twenty":-64.460997,"median":-48.969529,"eighty":-13.233973,"marketCap":18117765601},{"date":"2025-12-19","current":-71.875632,"twenty":-65.413889,"median":-52.055133,"eighty":-13.542645,"marketCap":17587353357},{"date":"2025-12-24","current":-73.927127,"twenty":-69.382811,"median":-55.337969,"eighty":-13.579586,"marketCap":18145682035},{"date":"2026-01-02","current":-79.895405,"twenty":-70.540926,"median":-57.311117,"eighty":-13.748078,"marketCap":19687798475},{"date":"2026-01-09","current":-85.854057,"twenty":-72.056904,"median":-58.941314,"eighty":-13.964201,"marketCap":21208805289},{"date":"2026-01-16","current":-80.413876,"twenty":-72.839385,"median":-59.401661,"eighty":-14.164153,"marketCap":19929453763},{"date":"2026-01-23","current":-77.735339,"twenty":-73.262106,"median":-59.808211,"eighty":-14.656731,"marketCap":19247132950},{"date":"2026-01-30","current":-73.838267,"twenty":-73.550435,"median":-60.0941,"eighty":-15.472199,"marketCap":18365801899},{"date":"2026-02-06","current":-69.490034,"twenty":-73.32273,"median":-60.154331,"eighty":-16.538679,"marketCap":17328105662},{"date":"2026-02-13","current":-71.473742,"twenty":-73.562339,"median":-60.192909,"eighty":-17.006135,"marketCap":17925136373},{"date":"2026-02-20","current":-71.065981,"twenty":-73.716985,"median":-60.392128,"eighty":-17.056006,"marketCap":17797201221},{"date":"2026-02-27","current":-72.540901,"twenty":-73.438012,"median":-60.796223,"eighty":-17.950543,"marketCap":18365801899},{"date":"2026-03-06","current":-68.036226,"twenty":-73.352041,"median":-61.160082,"eighty":-18.384598,"marketCap":17086450373},{"date":"2026-03-13","current":-60.794114,"twenty":-73.299371,"median":-60.919795,"eighty":-18.597951,"marketCap":15338003289},{"date":"2026-03-20","current":-67.303035,"twenty":-73.275932,"median":-61.206433,"eighty":-18.84686,"marketCap":16915870170},{"date":"2026-03-27","current":-68.867925,"twenty":-73.269478,"median":-61.274827,"eighty":-18.985169,"marketCap":16247764373},{"date":"2026-04-02","current":-85.055535,"twenty":-73.278872,"median":-61.433108,"eighty":-19.026504,"marketCap":20163286400},{"date":"2026-04-10","current":-78.454069,"twenty":-73.369897,"median":-61.662876,"eighty":-19.045802,"marketCap":18741784705},{"date":"2026-04-17","current":-76.94604,"twenty":-73.948705,"median":-62.45145,"eighty":-19.079188,"marketCap":18389252284},{"date":"2026-04-24","current":-60.4786,"twenty":-73.948705,"median":-62.528681,"eighty":-19.126247,"marketCap":14454535592},{"date":"2026-05-15","current":-17.642518,"twenty":-73.927127,"median":-62.346137,"eighty":-19.115451,"marketCap":4376314243},{"date":"2026-05-22","current":-20.448357,"twenty":-73.838267,"median":-61.433108,"eighty":-19.16943,"marketCap":5060724424},{"date":"2026-05-27","current":-13.89213,"twenty":-73.777626,"median":-61.31588,"eighty":-19.117647,"marketCap":3449427312}],"updateTime":1779969672392},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02565\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2638642026","title":"派格生物醫藥-B(02565)：維培那肽注射液納入2026年第二批參照藥預溝通增補藥品信息公示","url":"https://stock-news.laohu8.com/highlight/detail?id=2638642026","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638642026?lang=zh_tw&edition=fundamental","pubTime":"2026-05-28 18:18","pubTimestamp":1779963488,"startTime":"0","endTime":"0","summary":"智通财经APP讯，派格生物医药-B 发布公告，根据国家医疗保障局于2026年5月27日发布的《关于2026年第二批参照药预沟通增补药品信息的公示》，本公司申报的维培那肽注射液相关材料经反馈后已被确认符合2026年第二批参照药预沟通的申报要求，并已纳入本次增补药品信息公示范围。本次进入增补公示范围，标志着维培那肽注射液在国家医保参照药预沟通相关工作中取得阶段性进展，有助于后续参照药确认、医保准入及支付管理相关工作的有序推进。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447239.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["161726","BK4581","BK1161","399441","02565","BK4588","BK4585","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140836570","title":"異動解讀 | 派格生物醫藥-B盤中大漲5.33%，超跌反彈成主因","url":"https://stock-news.laohu8.com/highlight/detail?id=1140836570","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140836570?lang=zh_tw&edition=fundamental","pubTime":"2026-05-28 09:33","pubTimestamp":1779931980,"startTime":"0","endTime":"0","summary":"派格生物医药-B今日盘中大涨5.33%，引起了市场的广泛关注。消息面上，该股昨日因上市满一周年，IPO前股东所持股份禁售期全面到期，大量低成本筹码集中解禁，导致股价出现急跌。经历昨日重挫后，今日股价出现技术性超跌反弹。派格生物医药是一家深耕慢病代谢领域的生物科技公司，核心产品为接近商业化阶段的长效GLP-1受体激动剂PB-119，主要用于治疗2型糖尿病及肥胖症等代谢疾病。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184530545","title":"異動解讀｜派格生物醫藥-B盤中上漲10.77%，解禁拋壓集中釋放後技術性反彈","url":"https://stock-news.laohu8.com/highlight/detail?id=1184530545","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184530545?lang=zh_tw&edition=fundamental","pubTime":"2026-05-28 09:31","pubTimestamp":1779931884,"startTime":"0","endTime":"0","summary":"5月28日，派格生物医药-B盘中上涨10.77%，报9.71港元/股，成交额365.18万港元。消息面上，该股昨日恰逢上市满一周年，IPO前股东所持股份禁售期全面到期，大量低成本筹码集中解禁，盘中一度重挫逾15%，股价最低触及8.78港元。派格生物医药是一家深耕慢病代谢领域的生物科技公司，核心产品为接近商业化阶段的长效GLP-1受体激动剂PB-119，主要用于治疗2型糖尿病及肥胖症等代谢疾病。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116027974","title":"異動解讀｜派格生物醫藥-B盤中下跌15.99%，上市滿周年禁售期全面解禁引發拋壓","url":"https://stock-news.laohu8.com/highlight/detail?id=1116027974","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116027974?lang=zh_tw&edition=fundamental","pubTime":"2026-05-27 09:39","pubTimestamp":1779845942,"startTime":"0","endTime":"0","summary":"5月27日，派格生物医药-B盘中下跌15.99%，报9.29港元/股，成交额4687.47万港元。消息面上，派格生物医药-B于去年5月27日在港交所挂牌上市，今日恰逢上市满一周年，IPO前股东所持股份禁售期全面到期，大量低成本筹码集中解禁。派格生物医药是一家深耕慢病代谢领域的生物科技公司，核心产品为接近商业化阶段的长效GLP-1受体激动剂PB-119，主要用于治疗2型糖尿病及肥胖症等代谢疾病。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638534935","title":"格隆匯個股放量排行榜 | 5月25日","url":"https://stock-news.laohu8.com/highlight/detail?id=2638534935","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638534935?lang=zh_tw&edition=fundamental","pubTime":"2026-05-25 17:30","pubTimestamp":1779701404,"startTime":"0","endTime":"0","summary":"股票名称成交额（万）量比持续放量天数天利控股集团26177.222.493百富环球2703.382.425中联发展控股1067.482.361优必选217973.061.981华润医疗1719.231.911滔搏3529.591.832胜宏科技350159.461.791数码通电讯961.431.781九龙仓集团17387.851.641蔚来-SW46990.051.551高鑫零售1589.461.521科伦博泰生物60133.001.496九福来102.461.451中集集团7903.471.441北大青鸟环宇360.511.371PACIFIC LEGEND740.851.361中海油田服务9347.601.361MOS HOUSE695.301.331百果园集团641.011.291中芯国际1651388.781.282量化派3423.981.231佰泽医疗5107.781.191时代天使8886.501.192五一视界215348.591.182稀美资源-五百6200.381.1710电讯盈科6323.451.171美格智能7545.751.171深圳高速公路股份1185.201.172森松国际19247.321.143兖矿能源47039.851.111大象未来集团855.821.091通通AI社交2016.021.061兆易创新243","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/05/25173057187788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["09869","03888","00117","00004","01919","02418","02598","02714","06603","00199","06955","02155","00008","02587","00384","02050","01211","06613","06990","00081","01516","02685","01672","08547","09926","02172","00152","00107","02565","09993","02506","01477","01473","01592","02142","09626","02609","00981","03986","09866","00165","00909","06681","00177","06699","09880","06110","00087","02259","02291"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1134750431","title":"異動解讀 | 派格生物醫藥-B盤中大漲5.02%，核心藥物商業化合作獲重大進展","url":"https://stock-news.laohu8.com/highlight/detail?id=1134750431","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134750431?lang=zh_tw&edition=fundamental","pubTime":"2026-05-22 11:25","pubTimestamp":1779420312,"startTime":"0","endTime":"0","summary":"派格生物医药-B今日盘中大涨5.02%，股价表现强劲。消息面上，此次上涨主要得益于公司核心产品商业化取得重大进展。派格生物此前已与腾瑞制药就其核心产品派达康签署了在中国大陆的独家商业化战略合作协议，双方确立了累计销售规模超100亿元人民币的核心目标，腾瑞制药将为此支付约1.4亿港元的权益金。此次商业化合作的落地，被视为公司价值兑现的关键一步。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191908717","title":"異動解讀｜派格生物醫藥-B盤中上漲7.54%，GLP-1藥物商業化預期疊加短期超跌反彈","url":"https://stock-news.laohu8.com/highlight/detail?id=1191908717","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191908717?lang=zh_tw&edition=fundamental","pubTime":"2026-05-22 11:23","pubTimestamp":1779420239,"startTime":"0","endTime":"0","summary":"5月22日，派格生物医药-B盘中上涨7.54%，报13.81港元，成交额3346.31万港元，在前一交易日下跌5.14%后出现反弹。5月12日，方舟健客与腾瑞制药签署战略合作，派达康将在其互联网医院平台全网首发。派格生物医药是一家专注慢性病创新疗法的公司，核心产品PB-119为中国国内最早研发的长效GLP-1受体激动剂之一，主要覆盖2型糖尿病、肥胖症等代谢疾病领域。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136148056","title":"異動解讀 | 派格生物醫藥-B盤中大跌6.96%，前期暴漲後技術性回調","url":"https://stock-news.laohu8.com/highlight/detail?id=1136148056","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136148056?lang=zh_tw&edition=fundamental","pubTime":"2026-05-21 10:07","pubTimestamp":1779329251,"startTime":"0","endTime":"0","summary":"派格生物医药-B今日盘中股价大跌6.96%，引起了市场的关注。消息面上，该股此前因与腾瑞制药就GLP-1类药物派达康达成中国大陆独家商业化合作，股价在前期经历了连续大幅拉升，短期累计涨幅显著。经历暴涨后，当前成交额较前期明显萎缩，股价出现技术性回调。根据合作协议，双方确立了累计销售规模超人民币100亿元的核心商业化目标，腾瑞制药将支付合计约1.4亿港币权益金，派达康近期将在方舟健客互联网医院平台全网首发。尽管同期生物科技板块整体表现偏强，但该股在获利了结压力下逆市下跌。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101258599","title":"異動解讀｜派格生物醫藥-B盤中下跌5.14%，前期暴漲後回調縮量","url":"https://stock-news.laohu8.com/highlight/detail?id=1101258599","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101258599?lang=zh_tw&edition=fundamental","pubTime":"2026-05-21 10:04","pubTimestamp":1779329065,"startTime":"0","endTime":"0","summary":"5月21日，派格生物医药-B盘中下跌5.14%，报14.41港元，成交额2821.55万港元。该股此前因与腾瑞制药就GLP-1类药物派达康达成中国大陆独家商业化合作，于5月18日尾盘一度飙升超150%，收涨66.31%，5月19日再涨10.91%。消息面上，双方确立累计销售规模超人民币100亿元的核心商业化目标，腾瑞制药将支付合计约1.4亿港币权益金，派达康近期将在方舟健客互联网医院平台全网首发。同期生物科技板块整体表现偏强，康方生物涨6.87%、荣昌生物涨5.13%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637081378","title":"派格生物醫藥－Ｂ(02565)股價下跌5.007%，現價港幣$14.61","url":"https://stock-news.laohu8.com/highlight/detail?id=2637081378","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637081378?lang=zh_tw&edition=fundamental","pubTime":"2026-05-21 09:55","pubTimestamp":1779328500,"startTime":"0","endTime":"0","summary":"[下跌股]派格生物医药－Ｂ(02565) 股价在上午09:55比前收市价下跌5.007%，现股价为港币$14.61。至目前为止，今日最高价为$15.59，而最低价为$14.61。总成交量为147.565万股，总成交金额为港币$2.218千万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180725131627024_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180725131627024_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD260521780/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD260521780/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["399441","161726","02565","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146687816","title":"異動解讀 | 派達康商業化加速，派格生物醫藥-B盤中大漲6.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=1146687816","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146687816?lang=zh_tw&edition=fundamental","pubTime":"2026-05-20 09:52","pubTimestamp":1779241978,"startTime":"0","endTime":"0","summary":"派格生物医药-B今日盘中大涨6.86%，引起了市场的广泛关注。消息面上，此次股价上涨主要得益于公司核心产品派达康的商业化进程显著加速。公司此前与腾瑞制药就派达康在中国大陆的独家商业化签署了战略合作协议，腾瑞制药将支付合计约1.4亿港币的权益金，双方确立了累计销售额超过100亿元人民币的核心目标。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154172456","title":"異動解讀｜派格生物醫藥-B盤中上漲8.37%，派達康商業化落地持續催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1154172456","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154172456?lang=zh_tw&edition=fundamental","pubTime":"2026-05-20 09:51","pubTimestamp":1779241879,"startTime":"0","endTime":"0","summary":"5月20日，派格生物医药-B盘中上涨8.37%，报17.47港元，成交额7232.33万港元。消息面上，公司核心产品派达康商业化进程加速。此前公司与腾瑞制药就派达康中国大陆独家商业化签署战略合作协议，腾瑞制药将支付合计约1.4亿港币权益金，双方确立累计销售超100亿元人民币的核心目标。5月12日，方舟健客与腾瑞制药达成战略合作，派达康将于近期在其互联网医院平台全网首发，标志着该GLP-1创新药正式进入商业化放量阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636855893","title":"派格生物醫藥-B(02565)提名廖亦琳為獨立非執行董事候選人","url":"https://stock-news.laohu8.com/highlight/detail?id=2636855893","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636855893?lang=zh_tw&edition=fundamental","pubTime":"2026-05-19 19:44","pubTimestamp":1779191040,"startTime":"0","endTime":"0","summary":"于2026年5月19日，董事会已审议并批准相关决议案，提名廖亦琳女士为公司第二届董事会独立非执行董事候选人。廖亦琳女士的任期将自公司股东大会批准当日起至第二届董事会任期届满时止。待廖亦琳女士于股东大会上获选为独立非执行董事后，廖亦琳女士将接替范新鹏女士担任审计委员会主席以及薪酬与考核委员会及提名委员会各自的成员，任期与其担任第二届董事会独立非执行董事的任期一致。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443578.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK1161","399441","BK4588","02565","161726","XBI","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173899166","title":"異動解讀 | 派達康商業化合作持續催化，派格生物醫藥-B盤中大漲28.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=1173899166","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173899166?lang=zh_tw&edition=fundamental","pubTime":"2026-05-19 10:21","pubTimestamp":1779157296,"startTime":"0","endTime":"0","summary":"派格生物医药-B今日盘中大涨28.96%，引起了市场的广泛关注。消息面上，此次大涨主要得益于公司核心产品派达康（维培那肽注射液）的商业化合作取得显著进展。公司此前与腾瑞制药就派达康在中国大陆地区签署了独家商业化战略合作协议，双方确立了累计销售规模超100亿元人民币的核心目标，腾瑞制药将支付合计约1.4亿港币的权益金。此外，方舟健客与腾瑞制药已完成战略签约，派达康将于近期在其互联网医院平台全网首发，这标志着该产品的商业化落地进程正在加速。这些积极的市场消息持续催化了投资者的乐观情绪，推动了股价的强劲表现。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636302846","title":"港股異動 | 派格生物醫藥-B(02565)尾盤飆升150% 此前與騰瑞製藥達成派達康中國大陸獨家商業化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2636302846","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636302846?lang=zh_tw&edition=fundamental","pubTime":"2026-05-18 15:43","pubTimestamp":1779090229,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，派格生物医药-B(02565)尾盘飙升150%，截至发稿，涨106.97%，报23.16港元，成交额7.84亿港元。消息面上，派格生物医药今年3月公布，与腾瑞制药就派达康在中国大陆地区的商业化合作签署战略合作协议。双方在合作协议中确立以实现累计销售规模超过人民币100亿元作为核心商业化目标。根据合作协议，腾瑞制药将向公司支付合计约1.4亿港币的权益金。值得注意的是，5月12日，方舟健客与腾瑞制药举行战略合作签约仪式。本次战略签约后，备受瞩目的创新GLP-1类药物派达康（维培那肽注射液）将于近期在方舟健客互联网医院平台全网首发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442854.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK1191","BK1161","01477","399441","BK4588","02565","161726","BK1574","XBI","VXUS","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636040660","title":"派格生物醫藥－Ｂ(02565)股價顯著上升11.171%，現價港幣$12.44","url":"https://stock-news.laohu8.com/highlight/detail?id=2636040660","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636040660?lang=zh_tw&edition=fundamental","pubTime":"2026-05-18 15:05","pubTimestamp":1779087900,"startTime":"0","endTime":"0","summary":"[上升股]派格生物医药－Ｂ(02565) 股价在下午03:05比前收市价显著上升11.171%，现股价为港币$12.44。至目前为止，今日最高价为$12.44，而最低价为$9.75。总成交量为1.232千万股，总成交金额为港币$1.325亿。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180725133914771_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180725133914771_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2605182231/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2605182231/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["161726","02565","399441","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636304327","title":"「2026智通財經夏季路演大會」活動報名中 ！","url":"https://stock-news.laohu8.com/highlight/detail?id=2636304327","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636304327?lang=zh_tw&edition=fundamental","pubTime":"2026-05-18 10:06","pubTimestamp":1779069961,"startTime":"0","endTime":"0","summary":"5月28日，深圳前海。40+港股上市公司集中路演，与机构及高净值投资者面对面交流。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20260518/20260518102433_43763.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260518/20260518102433_43763.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442727.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["06938","06051","02659","06090","01021","01907","08299","01333","02670","02411","02652","02729","02526","03858","09696","02650","06651","00290","02623","BK1100","02726","01300","BK1155","03317","00363","02889","LU0314109678.HKD","06636","02575","00400","LU0287142896.SGD","VXUS","02142","02228","02565","LU0307460666.USD","02706","01384","06682","HK0001040143.USD","02675","00650","01378","01396","00305","03881","02655","00826","02685","BK1171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635395276","title":"派格生物醫藥－Ｂ(02565)股價下跌5.141%，現價港幣$22.88","url":"https://stock-news.laohu8.com/highlight/detail?id=2635395276","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635395276?lang=zh_tw&edition=fundamental","pubTime":"2026-05-13 11:52","pubTimestamp":1778644320,"startTime":"0","endTime":"0","summary":"[下跌股]派格生物医药－Ｂ(02565) 股价在上午11:52比前收市价下跌5.141%，现股价为港币$22.88。至目前为止，今日最高价为$27.08，而最低价为$22.88。总成交量为109.135万股，总成交金额为港币$2.689千万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180725131625844_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180725131625844_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2605132081/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2605132081/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["161726","02565","399441","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633483245","title":"派格生物醫藥－Ｂ(02565)股價上升8.679%，現價港幣$27.8","url":"https://stock-news.laohu8.com/highlight/detail?id=2633483245","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633483245?lang=zh_tw&edition=fundamental","pubTime":"2026-05-08 11:55","pubTimestamp":1778212500,"startTime":"0","endTime":"0","summary":"[上升股]派格生物医药－Ｂ(02565) 股价在上午11:55比前收市价上升8.679%，现股价为港币$27.8。至目前为止，今日最高价为$27.8，而最低价为$25.16。总成交量为9.39万股，总成交金额为港币$247.852万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2605082844/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2605082844/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["161726","02565","BK1161","399441"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127496308","title":"派格生物醫藥-B2026年4月股份維持穩定 無新增發行或回購","url":"https://stock-news.laohu8.com/highlight/detail?id=1127496308","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127496308?lang=zh_tw&edition=fundamental","pubTime":"2026-05-06 16:48","pubTimestamp":1778057312,"startTime":"0","endTime":"0","summary":"派格生物医药（杭州）股份有限公司于2026年5月6日发布了截至2026年4月30日的月度证券变动报告。报告显示，公司本月未进行新增发行、购回、注销或库藏股变动，股本结构保持稳定。根据公告，普通股H股的已发行股数月末结存为284,300,339股，与上月相同。注册股本合计为人民币391,091,532元，与上月保持一致。截至4月底，H股公众持股比例符合港交所上市规则要求。公司表示，将继续严格遵守香港联合交易所有限公司上市规则及相关法律法规的各项要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"8d4c202617d87be1d9fe31f833a300a8","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":98,"code":"91000000","status":"200"}]}}